IFRX
NASDAQ
$1.82
InflaRx N.V. (IFRX)
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $7.80 (+328.57%)
Market Cap
$182M
Free Cash Flow Yield
-18.58%
Beta (5Y)
1.20
Price Chart
Valuation
Market Cap$182M
P/S6161.81
P/B4.30
Profitability
Total Revenue (TTM)$33K
Gross Profit (TTM)-$8.35M
EBITDA-$55M
Operating Margin-144770%
EPS-$0.71
Financial Health
Debt-to-Equity2.2%
Free Cash Flow Yield-18.58%
Growth & Risk
EPS 5Y CAGR-12.08%
FCF 5Y CAGR-4.63%
Beta (5Y)1.20
Sharpe Ratio1.16